Shifting paradigms in multiple sclerosis: from disease-specific, through population-specific toward patient-specific.

@article{Golan2016ShiftingPI,
  title={Shifting paradigms in multiple sclerosis: from disease-specific, through population-specific toward patient-specific.},
  author={Daniel Golan and Elsebeth Staun-ram and Ariel Miller},
  journal={Current Opinion in Neurology},
  year={2016}
}
PURPOSE OF REVIEW In recent years we notice paradigm shifts in the understanding of multiple sclerosis (MS), leading to important transition in the patients' management. This review discusses some of the recent findings and developments underlying the conceptual changes being translated from 'treating the disease' to 'treating the patient' with MS (PwMS). RECENT FINDINGS Applying advanced technologies combined with cross-disciplinary efforts in the fields of neuropathology, neuroimmunology… 
View on Wolters Kluwer
ncbi.nlm.nih.gov
11 Citations
Background Citations
1
Results Citations
1

11 Citations

Digital Twins for Multiple Sclerosis
TLDR
The use of digital twins for MS is discussed as a revolutionary tool to improve diagnosis, monitoring and therapy refining patients’ well-being, saving economic costs, and enabling prevention of disease progression.
Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
TLDR
An overview of the role of IFN in the treatment of MS is provided and the available evidence for pegylated IFN therapy in MS is evaluated.
Multiple sclerosis: renaming the notorious and historical diagnosis?
TLDR
The notorious ‘MS’ label should be updated, perhaps by removing the reference to high recurrence of the disease (‘multiple’) or replacing ‘sclerosis’, which is a noun that carries a morbid connotation.
Focus group on the experience of patients and family members in the multiple sclerosis unit of a tertiary hospital
GP6 rs2304166 polymorphism is associated with response to natalizumab in multiple sclerosis patients
TLDR
The findings suggest the need to investigate GP6’s rs2304166 role as a potential pharmacogenetic predictor for MS patients’ response to natalizumab.
Latitude, Vitamin D, Melatonin, and Gut Microbiota Act in Concert to Initiate Multiple Sclerosis: A New Mechanistic Pathway
TLDR
Current findings on the correlation between latitude, sunlight and vitamin D, and their effects on intestinal calcium absorption, gut microbiota and neuroinflammatory mediators in MS are summarized and a new mechanistic pathway for the initiation of MS is proposed.
The road ahead for health and lifespan interventions
Recognizing the need for personalization of haemophilia patient‐reported outcomes in the prophylaxis era
TLDR
The underlying rationale for GAS and one other novel approach to PRO personalization are presented, and their potential to augment current outcome measures by reliably detecting and quantifying treatment effects in individuals with haemophilia on prophylaxis is discussed.
Promoting Collaborations Between Radiologists and Scientists.
SERUM LACTATE AS A BIOMARKER IN MULTIPLE SCLEROSIS
TLDR
This dissertation aims to provide a history of neurology in Egypt from 1989 to 2002, a period chosen in order to explore its roots as well as specific cases up to and including the year in which Mohamed El-Sheikh University was founded.
...
...

References

SHOWING 1-10 OF 91 REFERENCES
Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets
TLDR
The goal of this review is to summarize how B-cells may contribute to MS pathogenesis and thereby provide a basis for understanding why B-cell depletion is so effective in the treatment of this disease.
Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future
TLDR
The objective of this article is to review and discuss the current literature on body fluid biomarkers in MS, including research on potential biomarker candidates in the areas of miRNA, mRNA, lipids and proteins.
Cerebrospinal fluid proteomics in multiple sclerosis.
Pharmacogenomics of interferon-β in multiple sclerosis: what has been accomplished and how can we ensure future progress?
The increasing incidence and prevalence of female multiple sclerosis--a critical analysis of potential environmental factors.
Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
TLDR
An overview of the role of IFN in the treatment of MS is provided and the available evidence for pegylated IFN therapy in MS is evaluated.
Peripheral blood biomarkers in multiple sclerosis.
Biomarkers of interferon Beta therapy in multiple sclerosis.
  • J. Graber, S. Dhib-jalbut
  • Biology, Medicine
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • 2014
TLDR
Biomarkers may help elucidate the beneficial effects of IFNβ in MS and possibly guide therapeutic decision making given the variety of different therapies now available with varying mechanisms of action and risks.
Signaling networks in MS: A systems-based approach to developing new pharmacological therapies
TLDR
Together, data suggest that MS is likely to be associated with abnormalities in apoptosis/cell death, microglia activation, blood-brain barrier functioning, immune responses, cytokine production, and/or oxidative stress, although which pathways contribute to the cascade of damage and can be modulated remains an open question.
CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome
TLDR
The association of NFH levels with brain volume but not lesion volume changes supports the association of these markers with axonal damage, and results confirm increased neurofilament levels already in CIS being related to the level of physical disability.
...
...